A novel anti-ischemic stroke candidate drug AAPB with dual effects of neuroprotection and cerebral blood flow improvement

• DOI: 10.1016/j.apsb.2024.12.042
• Publication Date: 2025-01-23T18:53:54Z
• Authors: Jianbing Wu; Duorui Ji; Weijie Jiao; Jian Jia; Jiayi Zhu; Taijun Hang; Xijing Chen; Yang Ding; Yuwen Xu; Xinglong Chang; Liang Li; Qiu Liu; Yumei Cao; Yan Zhong; Xia Sun; Qingming Guo; Tuanjie Wang; Zhenzhong Wang; Ya Ling; Wei Xiao; Zhangjian Huang; Yihua Zhang
• Keywords: Stroke

Ischemic stroke (IS) is a globally life-threatening disease. Presently, few therapeutic medicines are available for treating IS, and rt-PA the only drug approved by US Food Drug Administration (FDA) in US. In fact, many agents showing excellent neuroprotection but no blood flow-improving activity animals have not achieved ideal clinical efficacy, while thrombolytic drugs improving flow without limited their wider application. To address these challenges meet huge unmet need, we designed identified novel compound AAPB with dual effects of cerebral improvement. significantly reduced infarction neural function deficit tMCAO rats, pMCAO IS rhesus monkeys, as well displayed exceptional safety profiles pharmacokinetic properties rats dogs. has now entered phase I trials fighting China.